Amgen, Inc. (AMGN) Shares Bought by Cascade Investment Advisors Inc.

Cascade Investment Advisors Inc. raised its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,100 shares of the medical research company’s stock after acquiring an additional 75 shares during the quarter. Amgen makes up about 1.2% of Cascade Investment Advisors Inc.’s holdings, making the stock its 19th largest holding. Cascade Investment Advisors Inc.’s holdings in Amgen were worth $1,349,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Ruggie Capital Group increased its holdings in shares of Amgen by 297.1% in the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 101 shares during the last quarter. Capital Financial Planning LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $27,000. Massey Quick Simon & CO. LLC increased its holdings in shares of Amgen by 710.5% in the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 135 shares during the last quarter. Next Capital Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $33,000. Finally, Essex Investment Management Co. LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $39,000. 80.65% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts recently commented on the company. Oppenheimer set a $224.00 price target on Amgen and gave the company a “buy” rating in a report on Sunday, January 27th. Mizuho reissued a “buy” rating and set a $211.00 target price on shares of Amgen in a research note on Tuesday, February 26th. BidaskClub cut Amgen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 20th. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. Finally, BMO Capital Markets initiated coverage on Amgen in a research note on Thursday, March 14th. They set an “outperform” rating and a $228.00 target price for the company. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $208.84.

In other news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $175.73, for a total transaction of $351,460.00. Following the completion of the transaction, the director now directly owns 15,092 shares in the company, valued at $2,652,117.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last 90 days, insiders have sold 6,000 shares of company stock valued at $1,115,580. Company insiders own 0.25% of the company’s stock.

AMGN stock opened at $167.81 on Wednesday. The company has a quick ratio of 2.53, a current ratio of 2.77 and a debt-to-equity ratio of 2.71. The firm has a market cap of $102.23 billion, a price-to-earnings ratio of 11.56, a price-to-earnings-growth ratio of 2.21 and a beta of 1.15. Amgen, Inc. has a 52-week low of $167.17 and a 52-week high of $210.19.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, topping the consensus estimate of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The business had revenue of $5.56 billion during the quarter, compared to analyst estimates of $5.55 billion. During the same period last year, the business posted $3.47 earnings per share. The company’s quarterly revenue was up .1% on a year-over-year basis. As a group, equities research analysts anticipate that Amgen, Inc. will post 13.93 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a dividend yield of 3.46%. Amgen’s dividend payout ratio is currently 40.28%.

TRADEMARK VIOLATION WARNING: This piece was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/15/amgen-inc-amgn-shares-bought-by-cascade-investment-advisors-inc.html.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: What is a Stop Order?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.